November 9, 2022
November 9, 2022
SINGAPORE – November 9, 2022 – Lion TCR announced the abstract of a Phase I clinical trial for primary hepatitis B virus (HBV)-related hepatocellular carcinoma (NCT03899415) has been reported at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2022 as a poster presentation.
Title: Analysis of Biochemical and Immunological Alterations in Disease Control Group VS Disease Progression Group after Hepatitis B virus (HBV)-specific T-cell receptor (TCR) T cell therapy for Primary HBV-related Hepatocellular Carcinoma
Abstract No: 5056
Study Principal Investigator & Corresponding Author: Wang Fu Sheng
First Author: Meng Fan Ping
Patients with clinical response showed larger degree of reversible localized liver inflammation and larger anti-viral response, suggesting the on-target effects of LioCyx-M.
Importantly, patients with clinical response displayed activation of proliferative T-cell compartment and/or elevations of serum inflammatory chemokines, CXCL9 and CXCL10. These biomarker changes are suggestive of the activation of secondary immune responses resulting in a durable efficacy of these functionally short-lived HBV-specific TCR-T cells, which could explain the longer OS in this group of patients.
In contrast, non-responders did not display any detectable peripheral blood immunological alterations.
The data conclusively demonstrated the differential liver function, viral and immune alterations in patient with and without clinical response, implicating the importance of secondary immune response activation via the cancer-immunity cycle for durable anti-tumor effects of LioCyx-M.
This data highlights the promising use of HBV-specific TCR-T therapy in HBV-related HCC, and the same technology could potentially be extended to the treatment of other solid tumors in future.
About Lion TCR
Lion TCR is a Singapore based clinical-stage biotechnology company, focused on the development of T cell receptor (TCR)-T cell therapy against life-threatening viral infections and viral-related cancers.
LioCyx-M, including several well-established product derivatives, are autologous T cells modified to express HBV-specific TCR. These modified T cells have been shown to be able to lyse HBV-infected HCC cells upon target recognition in various in vivo pre-clinical studies and in patients.
Lion TCR Clinched The "Outstanding Innovative Award" At The 2023 Cell And Gene Therapy (CGT) Asia Innovation Summit.
Lion TCR Announces Poster Presentation of Phase 1 Study for Lead Product LioCyx-M at AASLD The Liver Meeting 2022
Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma
Scientific Founder & Chairman, Professor Antonio Bertoletti Has Been Placed on Highly Cited Researchers 2021 List
Lion TCR Announces FDA Clearance of its IND Application for its Lead Investigational Product, LioCyx-M004, for Hepatocellular Carcinoma
Scientific Founder, Prof Antonio Bertoletti Appointed as Cellular Immunotherapy Infectious Diseases Lead for Singhealth Duke-NUS Cell Therapy Centre
Lion TCR Licenses and Duke-NUS Medical School ink an exclusive IP licensing agreement for Immunosuppressive Drug Resistant Anti-Cancer T-cells
Dr Wai Lu-En, Director of R&D, represented Lion TCR to share the latest developments to the Minister for Manpower and Second Minister for Trade and Industry Tan See Leng.
Scientific Founder, Prof Antonio Bertoletti Appointed in Cell and Gene Therapy Workgroup in Singapore
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient